Velocity Clinical Research is pleased to announce the appointment of Sarah Smiley, DO, FACP, as its new Chief Physician Officer (CPO), reinforcing the company’s commitment to clinical leadership as it continues to grow its global site network and deepen its therapeutic expertise. Dr. Smiley is a seasoned physician investigator with nearly two decades of experience … Read more
Velocity Principal Investigators Douglas K. Logan, MD, and David Ensz, MD, are authors of a newly published Nature Communications article, “Immunogenicity and safety of mRNA-based seasonal influenza vaccines encoding hemagglutinin and neuraminidase.” The Phase 1/2 Moderna trial results “demonstrate the proof of concept that mRNA-1020 and mRNA-1030 elicit similar HA-specific immune responses to [hemagglutinin] HA-only … Read more
Tremendous results! Julio Rosenstock, MD, recently authored and presented results for Lilly’s Phase 3 ACHIEVE-1 trial. The once-daily pill significantly reduced A1C (1.3-1.6%) and led to an average 16-pound weight loss. The results were presented by Dr. Rosenstock at the American Diabetes Association Scientific Sessions and published in The New England Journal of Medicine. “The … Read more
At Velocity Clinical Research, we’re proud to be one of the largest clinical trial patient networks in the world, with access to over one million patients in our database across more than 70 integrated sites. That scale puts us in a unique position to listen, learn, and lead—and it’s why we’re excited to share insights … Read more
VISION has now contributed to more than 10,000 participant randomizations worldwide. Additionally, over $12.6 million in stipends have been paid through the VISION Engage mobile app, which is active in four countries and available in four languages. VISION continues to connect more people to clinical trials, enhance the participant experience, and reduce site burden. Learn … Read more
Velocity’s sites in Dallas, TX, and Staszów, Poland, enrolled patients in Novo Nordisk’s Phase 3 trial assessing semaglutide’s effect on participants with metabolic dysfunction–associated steatohepatitis (MASH). Trial results were published in a recent New England Journal of Medicine article detailing the GLP-1 receptor agonist’s impact on liver fibrosis. The study found that “in patients with … Read more
Congratulations to our Annapolis, MD, site for being recognized as the top U.S. enroller in a Phase 3 respiratory trial. Established in partnership with Luminis Health, this site also marked Velocity’s entry into oncology in the U.S.
The pandemic left many notable developments in its wake, not least the increased focus on improving diversity in clinical trials. This issue was thrust into the spotlight during Operation Warp Speed — the accelerated development of a COVID-19 vaccine in the U.S. — and is one Jerome Adams, MD, MPH, who served as U.S. General … Read more
As Nick Spittal states in this Advarra press release, membership in the Gene Therapy Ready (GTR) site network “allows Velocity to start studies over a month faster and provides a meaningful credential and important validation that increases sponsors’ confidence in our specialized capabilities to conduct complex clinical research safely.” All Velocity sites are fully prepared … Read more
Kris Kowdley, MD, AGAF, FAASLD, FACP, FACG, played an integral role in the clinical research that first gained FDA approval in June 2024, and has now led to the European Union’s approval of Ipsen’s Iqirvo, a groundbreaking therapy for primary biliary cholangitis (PBC), a rare liver condition. As the lead investigator for the Phase 3 … Read more